Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 43.73 Million USD | -65.78% |
| 2022 | 127.81 Million USD | 1.12% |
| 2021 | 126.39 Million USD | -21.85% |
| 2020 | 161.72 Million USD | 123.36% |
| 2019 | 72.4 Million USD | 1.25% |
| 2018 | 71.5 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 43.76 Million USD | 1.13% |
| 2024 Q1 | 43.27 Million USD | -1.05% |
| 2023 Q2 | 129.69 Million USD | 0.14% |
| 2023 FY | 43.73 Million USD | -65.78% |
| 2023 Q4 | 43.73 Million USD | -46.29% |
| 2023 Q3 | 81.42 Million USD | -37.22% |
| 2023 Q1 | 129.51 Million USD | 1.33% |
| 2022 Q3 | 128.09 Million USD | 0.26% |
| 2022 Q2 | 127.76 Million USD | -0.05% |
| 2022 Q1 | 127.83 Million USD | 1.14% |
| 2022 FY | 127.81 Million USD | 1.12% |
| 2022 Q4 | 127.81 Million USD | -0.22% |
| 2021 Q2 | 158.77 Million USD | -1.96% |
| 2021 Q1 | 161.94 Million USD | 0.13% |
| 2021 FY | 126.39 Million USD | -21.85% |
| 2021 Q3 | 157.26 Million USD | -0.95% |
| 2021 Q4 | 126.39 Million USD | -19.63% |
| 2020 Q3 | 72.6 Million USD | 0.59% |
| 2020 Q4 | 161.72 Million USD | 122.76% |
| 2020 Q2 | 72.17 Million USD | 0.56% |
| 2020 Q1 | 71.77 Million USD | -0.87% |
| 2020 FY | 161.72 Million USD | 123.36% |
| 2019 FY | 72.4 Million USD | 1.25% |
| 2019 Q3 | 72.15 Million USD | 0.0% |
| 2019 Q1 | - USD | -100.0% |
| 2019 Q4 | 72.4 Million USD | 0.35% |
| 2018 FY | 71.5 Million USD | 0.0% |
| 2018 Q4 | 71.5 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| America Great Health | 1.12 Million USD | -3794.09% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | 1.29 Million USD | -3285.139% |
| Bio-Path Holdings, Inc. | 10 Thousand USD | -437260.0% |
| Better Therapeutics, Inc. | 10.34 Million USD | -322.652% |
| Calithera Biosciences, Inc. | 136 Thousand USD | -32058.824% |
| Comera Life Sciences Holdings, Inc. | 120.3 Thousand USD | -36255.173% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| Eloxx Pharmaceuticals, Inc. | 8.69 Million USD | -403.175% |
| Evelo Biosciences, Inc. | 48.87 Million USD | 10.522% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | -1068.241% |
| Finch Therapeutics Group, Inc. | 28.4 Million USD | -53.984% |
| Galera Therapeutics, Inc. | 151.04 Million USD | 71.045% |
| Innovation1 Biotech Inc. | 218.99 Thousand USD | -19870.867% |
| Kiromic BioPharma, Inc. | 911.5 Thousand USD | -4698.245% |
| Molecular Templates, Inc. | 9.74 Million USD | -348.943% |
| Navidea Biopharmaceuticals, Inc. | 1.87 Million USD | -2236.681% |
| NexImmune, Inc. | - USD | -Infinity% |
| Orgenesis Inc. | 19.06 Million USD | -129.381% |
| Panbela Therapeutics, Inc. | 4.19 Million USD | -942.823% |
| Point of Care Nano-Technology, Inc. | - USD | -Infinity% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 104.33 Million USD | 58.082% |
| Statera Biopharma, Inc. | 11.43 Million USD | -282.604% |
| TRACON Pharmaceuticals, Inc. | 732 Thousand USD | -5874.863% |
| Trevena, Inc. | 35.23 Million USD | -24.134% |
| Vaxxinity, Inc. | 13.26 Million USD | -229.784% |
| Vaccinex, Inc. | 26 Thousand USD | -168115.385% |
| Vicapsys Life Sciences, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| ZIVO Bioscience, Inc. | - USD | -Infinity% |